Why Farbe Firma is the Top Manufacturer of Neostigmine + Glycopyrrolate Injection
- Maulik Sudani
- 1 day ago
- 7 min read
Last Updated: May 28, 2026
TL;DR: Neostigmine + Glycopyrrolate Injection — a sterile parenteral fixed-dose combination of the reversible cholinesterase inhibitor neostigmine methylsulfate (typically 2.5 mg) with the synthetic quaternary-ammonium antimuscarinic glycopyrrolate (typically 0.5 mg) per 1 mL or 2 mL ampoule — is the global standard for routine reversal of non-depolarising neuromuscular blockade at the end of surgery. The combination delivers the cholinergic reversal effect of neostigmine while glycopyrrolate antagonises the muscarinic bradycardia, salivation and bronchospasm that would otherwise accompany it, giving anaesthetists a single, predictable, ready-to-administer ampoule. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Neostigmine + Glycopyrrolate Injection at our Gujarat, India facility and supplies it to operating-theatre tenders, hospital pharmacies, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Fixed-dose anticholinesterase + antimuscarinic combination — Neostigmine + Glycopyrrolate Injection is the operating-theatre standard for pharmacological reversal of rocuronium-, vecuronium-, atracurium- and pancuronium-induced neuromuscular blockade. The fixed glycopyrrolate-to-neostigmine ratio matches the onset of the two molecules and removes the need to draw up and dose-match two ampoules under time pressure at the end of a case.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified clear-glass ampoule filling lines, fixed-dose-combination blending and assay control for two distinct APIs in a single solution, validated terminal-sterilisation cycles and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for fixed-dose-combination registrations across regulated and emerging markets — including ministry-of-health anaesthesia and operating-theatre tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Neostigmine + Glycopyrrolate Injection Demands a Premium Manufacturer
Neostigmine + Glycopyrrolate Injection is the most widely used pharmacological reversal product in modern anaesthesia. At the end of a general-anaesthetic case the anaesthetist needs to restore neuromuscular function in seconds, without simultaneously dropping the patient's heart rate, drowning the airway in secretions, or triggering bronchospasm. Drawing up neostigmine and glycopyrrolate separately, calculating the ratio and pushing two ampoules at the right moment is workable but error-prone; a fixed-dose, single-ampoule combination is what most operating theatres want, because it removes a dose-calculation step at the busiest minute of the case and standardises practice across every anaesthetist in the hospital. The combination is also used for myasthenic patients undergoing surgery and for postoperative ileus reversal, again because the antimuscarinic balance protects the patient from neostigmine's peripheral cholinergic side effects.
That clinical reality places real demands on the manufacturer. A fixed-dose combination is not just two drugs in one ampoule — it is a single sterile solution in which two APIs of different pKa, different stability profile and different assay method have to coexist, hold their label ratio for the entire shelf life, and survive sterilisation, storage and shipping without one degrading faster than the other. Choosing a Neostigmine + Glycopyrrolate Injection manufacturer that treats two-API formulation, dual-analyte assay and fixed-ratio stability as core engineering disciplines is what keeps the operating-theatre reversal predictable across thousands of cases per week.
What Sets a World-Class Neostigmine + Glycopyrrolate Injection Manufacturer Apart
A world-class manufacturer of Neostigmine + Glycopyrrolate Injection invests in three areas that weaker suppliers underfund: dual-API assay and content-uniformity control, fixed-ratio stability tracking under ICH conditions, and a sterility and particulate programme built for a small-volume parenteral that will be pushed intravenously at the end of every anaesthetic. It starts with the active pharmaceutical ingredients — pharmacopoeial-grade neostigmine methylsulfate and glycopyrrolate sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect both molecules end to end. The solution is built to a controlled pH that holds both APIs stable, with stability-supporting excipients chosen for the combination rather than for either drug alone, and filled under ISO Class 5 air in clear-glass ampoules. In-process assay confirms label strength for both neostigmine and glycopyrrolate against the same release specification, container-closure integrity is verified, and stability is tracked under ICH Q1A long-term and accelerated conditions plus ICH Q1B photostability protocols — with the critical constraint that the two assay results must hold their fixed ratio across the entire shelf life. Artwork carries the fixed-dose ratio prominently so theatre staff can confirm dose at a glance.
Quality Systems Behind Every Neostigmine + Glycopyrrolate Injection
Every Farbe Firma Neostigmine + Glycopyrrolate Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards for both neostigmine methylsulfate and glycopyrrolate, related-substances and degradation-product profiling on both APIs, pH, osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification for both 1 mL and 2 mL ampoule formats. Certificates of analysis are issued with full traceability back to API lots for both molecules, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Neostigmine + Glycopyrrolate Injection they buy today will still hold its fixed-dose ratio when it reaches the operating theatre months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Neostigmine + Glycopyrrolate Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anaesthesia, critical-care, anti-infective, obstetric, neonatal and supportive-care categories. For Neostigmine + Glycopyrrolate Injection specifically, we supply the standard 2.5 mg neostigmine methylsulfate + 0.5 mg glycopyrrolate per mL combination in 1 mL and 2 mL clear-glass ampoules, with alternative ratios (including 1 mg neostigmine + 0.2 mg glycopyrrolate paediatric presentations), country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, fixed-dose-combination justification dossiers, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Neostigmine + Glycopyrrolate Injection at tender scale — and operating-theatre reversal procurements are almost always high-volume, anaesthesia-protocol-bound and labelling-sensitive — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through dual-API sourcing, fixed-ratio formulation, particulate control, sterilisation, container-closure and stability choices in real detail. For a combination drug given at the most fragile minute of the anaesthetic case, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Neostigmine + Glycopyrrolate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Neostigmine + Glycopyrrolate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles and continuous environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Neostigmine + Glycopyrrolate Injection do you supply?
Our standard presentation is 2.5 mg neostigmine methylsulfate + 0.5 mg glycopyrrolate per mL in 1 mL and 2 mL clear-glass ampoules. Alternative ratios (including paediatric 1 mg neostigmine + 0.2 mg glycopyrrolate ampoules), custom fill volumes, vial presentations and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Neostigmine + Glycopyrrolate Injection?
Yes. We provide full CTD and ACTD dossier modules, fixed-dose-combination justification packages, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia, including anaesthesia and operating-theatre tender programmes for ministry-of-health buyers.
How does Farbe Firma assure the fixed-dose ratio and stability of Neostigmine + Glycopyrrolate Injection?
We control pH within a validated specification chosen for the combination, run HPLC assay and related-substances testing for both APIs on every batch, package in pharmacopoeial glass with light-protective secondary cartons where required, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability — with the explicit constraint that the neostigmine-to-glycopyrrolate ratio must remain within specification across the entire shelf life. Endotoxin, sterility and container-closure integrity are confirmed on every batch.
What is the minimum order quantity for Neostigmine + Glycopyrrolate Injection contract manufacturing?
MOQs vary by ratio, container format, label complexity and dossier requirements. For both 1 mL and 2 mL ampoule presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments